Travere Therapeutics (TVTX)Officer filed to sell ~$13M

~$13M

planned to sell · 244K shares, around Oct 15, 2026

Planned for

Oct 15, 2026

Notice filed

Oct 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company effective as of December 1, 2026 (the “Officer Resignation Date”).”
2. Oct 15, 2026Insider · 1 personInsiders: 3 sales (~$13.1M)

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Travere Therapeutics

For Travere Therapeutics, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TVTX page.

How this filing works

• SEC Form 144
• Rule 10b5-1 trading plans

Other disclosures at Travere Therapeutics

• SEC Form 4Oct 19, 2026
• SEC Form 4Oct 19, 2026
• SEC Form 4Oct 19, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its TVTX page.